CSIMarket
 


Rocket Pharmaceuticals Inc   (RCKT)
Other Ticker:  
 

Rocket Pharmaceuticals Inc 's Quick Ratio

RCKT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Rocket Pharmaceuticals Inc 's Cash & cash equivalent grew by 42.38 % in the III Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Rocket Pharmaceuticals Inc 's Quick Ratio to 13.06, Quick Ratio remained below Rocket Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 68 other companies have achieved higher Quick Ratio than Rocket Pharmaceuticals Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 224, from total ranking in the second quarter 2023 at 398.

Explain Quick Ratio?
How much Cash & cash equivalents RCKT´s has?
What are RCKT´s Current Liabilities?


RCKT Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 10.92 % 41.41 % 38.26 % 76.7 % 23.24 %
Y / Y Cash & cash equivalent Change 42.62 % -4.46 % -4.47 % -8.32 % -27.27 %
Quick Ratio MRQ 13.06 8.94 10.61 9.1 10.16
RCKT's Total Ranking # 224 # 398 # 142 # 143 # 409
Seq. Current Liabilities Change -2.53 % 10.06 % -20.33 % 29.78 % 24.26 %
Seq. Cash & cash equivalent Change 42.38 % -7.26 % -7.1 % 16.27 % -4.62 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 114
Overall Market # 224


Quick Ratio Statistics
High Average Low
38.37 17.83 7.16
(Mar 31 2018)   (Sep 30 2020)




Financial Statements
Rocket Pharmaceuticals Inc 's Current Liabilities $ 33 Millions Visit RCKT's Balance sheet
Rocket Pharmaceuticals Inc 's Cash & cash equivalent $ 437 Millions Visit RCKT's Balance sheet
Source of RCKT's Sales Visit RCKT's Sales by Geography


Cumulative Rocket Pharmaceuticals Inc 's Quick Ratio

RCKT's Quick Ratio for the trailling 12 Months

RCKT Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 10.92 % 41.41 % 38.26 % 76.7 % 23.24 %
Y / Y Cash & cash equivalent TTM Growth 42.62 % -4.46 % -4.47 % -8.32 % -27.27 %
Quick Ratio TTM 10.36 9.64 10.54 11.45 13.74
Total Ranking TTM # 131 # 3255 # 1560 # 69 # 67
Seq. Current Liabilities TTM Growth -2.53 % 10.06 % -20.33 % 29.78 % 24.26 %
Seq. Cash & cash equivalent TTM Growth 42.38 % -7.26 % -7.1 % 16.27 % -4.62 %


On the trailing twelve months basis RCKT Cash & cash equivalent soared by 42.62 % in III Quarter 2023 year on year, faster than Current Liabilities, this led to increase in in Rocket Pharmaceuticals Inc 's Quick Ratio to 10.36, Quick Ratio remained below RCKT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 55 other companies have achieved higher Quick Ratio than Rocket Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 131, from total ranking during the twelve months ending second quarter 2023 at 3255.

Explain Quick Ratio?
How much Cash & cash equivalents RCKT´s has?
What are RCKT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 56
Healthcare Sector # 90
Within the Market # 131


trailing twelve months Quick Ratio Statistics
High Average Low
25.77 14.68 9.64
(Mar 31 2018)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Rayzebio Inc   34.09 $ 540.169  Millions$ 15.847  Millions
Cymabay Therapeutics Inc   31.72 $ 438.778  Millions$ 13.831  Millions
Atea Pharmaceuticals Inc   31.50 $ 595.126  Millions$ 18.893  Millions
Greenwich Lifesciences Inc   30.76 $ 9.144  Millions$ 0.297  Millions
Verona Pharma Plc  29.80 $ 257.366  Millions$ 8.636  Millions
Aprea Therapeutics Inc   29.39 $ 25.354  Millions$ 0.863  Millions
Theseus Pharmaceuticals Inc   29.29 $ 205.122  Millions$ 7.003  Millions
Viking Therapeutics Inc   28.75 $ 376.241  Millions$ 13.086  Millions
Karuna Therapeutics Inc   27.40 $ 1,341.510  Millions$ 48.968  Millions
Atossa Therapeutics Inc   27.33 $ 94.141  Millions$ 3.444  Millions
Disc Medicine Inc   25.70 $ 370.541  Millions$ 14.416  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.17 $ 349.712  Millions$ 14.471  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.06 $ 266.600  Millions$ 12.087  Millions
Cyteir Therapeutics Inc   21.65 $ 129.242  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.64 $ 241.902  Millions$ 11.180  Millions
Xenon Pharmaceuticals Inc   21.28 $ 526.674  Millions$ 24.744  Millions
Tyra Biosciences Inc   21.25 $ 215.652  Millions$ 10.147  Millions
Astria Therapeutics inc   21.23 $ 188.806  Millions$ 8.894  Millions
Sagimet Biosciences inc   20.59 $ 101.842  Millions$ 4.946  Millions
Eledon Pharmaceuticals Inc   20.56 $ 59.609  Millions$ 2.899  Millions
Acelyrin Inc   20.41 $ 381.738  Millions$ 18.702  Millions
Akero Therapeutics Inc   19.50 $ 554.732  Millions$ 28.447  Millions
Acasti Pharma Inc   19.33 $ 27.006  Millions$ 1.397  Millions
Pliant Therapeutics Inc   19.11 $ 523.612  Millions$ 27.395  Millions
Eqrx Inc   19.03 $ 1,212.933  Millions$ 63.726  Millions

Date modified: 2023-11-08T18:20:41+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com